Piper Sandler Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS - Get Free Report) had its price target cut by analysts at Piper Sandler from $40.00 to $15.00 in a report released on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Piper Sandler's price target would suggest a potential upside of 38.12% from the company's previous close.

KROS has been the topic of several other reports. Scotiabank lowered their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research report on Thursday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Keros Therapeutics in a report on Friday, November 22nd. William Blair cut Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Wedbush lowered Keros Therapeutics from an "outperform" rating to a "neutral" rating and decreased their price objective for the company from $47.00 to $15.00 in a research note on Friday. Finally, BTIG Research downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, December 12th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Keros Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $52.56.

Keros Therapeutics Stock Performance

KROS stock traded up $0.34 during midday trading on Friday, hitting $10.86. 2,986,409 shares of the stock were exchanged, compared to its average volume of 1,205,141. The stock's 50-day moving average price is $36.37 and its 200-day moving average price is $47.13. The stock has a market cap of $439.94 million, a price-to-earnings ratio of -2.08 and a beta of 1.43. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm's revenue was up 4750.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) earnings per share. Research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV raised its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Keros Therapeutics in the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics during the second quarter worth about $128,000. Finally, LMR Partners LLP purchased a new position in Keros Therapeutics in the 3rd quarter worth approximately $213,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.